Redefining sensor performance with advanced physical AI and signal processing.
Updated
January 8, 2026 6:32 PM
.jpg)
Robot with human features, equipped with a visual sensor. PHOTO: UNSPLASH
Atomathic, the company once known as Neural Propulsion Systems, is stepping into the spotlight with a bold claim: its new AI platforms can help machines “see the invisible”. With the commercial launch of AIDAR™ and AISIR™, the company says it is opening a new chapter for physical AI, AI sensing and advanced sensor technology across automotive, aviation, defense, robotics and semiconductor manufacturing.
The idea behind these platforms is simple yet ambitious. Machines gather enormous amounts of signal data, yet they still struggle to understand the faint, fast or hidden details that matter most when making decisions. Atomathic says its software closes that gap. By applying AI signal processing directly to raw physical signals, the company aims to help sensors pick up subtle patterns that traditional systems miss, enabling faster reactions and more confident autonomous system performance.
"To realize the promise of physical AI, machines must achieve greater autonomy, precision and real-time decision-making—and Atomathic is defining that future," said Dr. Behrooz Rezvani, Founder and CEO of Atomathic. "We make the invisible visible. Our technology fuses the rigor of mathematics with the power of AI to transform how sensors and machines interact with the world—unlocking capabilities once thought to be theoretical. What can be imagined mathematically can now be realized physically."
This technical shift is powered by Atomathic’s deeper mathematical framework. The core of its approach is a method called hyperdefinition technology, which uses the Atomic Norm and fast computational techniques to map sparse physical signals. In simple terms, it pulls clarity out of chaos. This enables ultra-high-resolution signal visualization in real time—something the company claims has never been achieved at this scale in real-time sensing.
AIDAR and AISIR are already being trialled and integrated across multiple sectors and they’re designed to work with a broad range of hardware. That hardware-agnostic design is poised to matter even more as industries shift toward richer, more detailed sensing. Analysts expect the automotive sensor market to surge in the coming years, with radar imaging, next-gen ADAS systems and high-precision machine perception playing increasingly central roles.
Atomathic’s technology comes from a tight-knit team with deep roots in mathematics, machine intelligence and AI research, drawing talent from institutions such as Caltech, UCLA, Stanford and the Technical University of Munich. After seven years of development, the company is ready to show its progress publicly, starting with demonstrations at CES 2026 in Las Vegas.
Suppose the future of autonomy depends on machines perceiving the world with far greater fidelity. In that case, Atomathic is betting that the next leap forward won’t come from more hardware, but from rethinking the math behind the signal—and redefining what physical AI can do.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.